Literature DB >> 10851074

PIK3CA as an oncogene in cervical cancer.

Y Y Ma1, S J Wei, Y C Lin, J C Lung, T C Chang, J Whang-Peng, J M Liu, D M Yang, W K Yang, C Y Shen.   

Abstract

Amplification of chromosome arm 3q is the most consistent aberration in cervical cancer, and is implicated in the progression of dysplastic uterine cervical cells into invasive cancer. The present study employed the 'positional candidate gene' strategy to determine the contribution of PIK3CA, which is located in 3q26.3, in cervical tumorigenesis. PIK3CA is known to be involved in the PI 3-kinase/AKT signaling pathway, which plays an important role in regulating cell growth and apoptosis. The results of comparative genomic hybridization show that the 3q26.3 amplification was the most consistent chromosomal aberration in primary tissues of cervical carcinoma, and a positive correlation between an increased copy number of PIK3CA (detected by competitive PCR) and 3q26.3 amplification was found in tumor tissues and in cervical cancer cell lines. In cervical cancer cell lines harboring amplified PIK3CA, the expression of gene product (p110alpha) of PIK3CA was increased, and was subsequently associated with high kinase activity. In addition, transformation phenotypes in these lines, including increased cell growth and decreased apoptosis, were found to be significantly affected by the treatment of specific PI 3-kinase inhibitor, suggesting that increased expression of PIK3CA in cervical cancer may result in promoting cell proliferation and reducing apoptosis. These evidences support that PIK3CA is an oncogene in cervical cancer and PIK3CA amplification may be linked to cervical tumorigenesis. Oncogene (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851074     DOI: 10.1038/sj.onc.1203597

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  117 in total

1.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

Review 2.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.

Authors:  Hongbo Chen; Lin Mei; Lanzhen Zhou; Xiaomeng Shen; Caiping Guo; Yi Zheng; Huijun Zhu; Yongqiang Zhu; Laiqiang Huang
Journal:  J Neurooncol       Date:  2010-12-29       Impact factor: 4.130

5.  Cancer-specific mutations in PIK3CA are oncogenic in vivo.

Authors:  Andreas G Bader; Sohye Kang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

6.  Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase.

Authors:  Manon J Winter; Vincenzo Cirulli; Inge H Briaire-de Bruijn; Sergey V Litvinov
Journal:  Mol Cell Biochem       Date:  2007-02-14       Impact factor: 3.396

7.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Authors:  Wanglong Qiu; Guo-Xia Tong; Spiros Manolidis; Lanny G Close; Adel M Assaad; Gloria H Su
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

9.  Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line.

Authors:  Jung Kyu Park; Chi Heum Cho; Sabarish Ramachandran; So Jin Shin; Sang Hoon Kwon; Sun Young Kwon; Soon Do Cha
Journal:  Cancer Res Treat       Date:  2006-04-30       Impact factor: 4.679

Review 10.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.